Fig. 2 | Genetics in Medicine

Fig. 2

From: Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting

Fig. 2

Cardiovascular or bleeding events over 12 months following percutaneous coronary intervention (PCI) by CYP2C19 status and initial and maintenance P2Y12 inhibitor therapy. a Study population summary by initial P2Y12 inhibitor, CYP2C19 phenotype, and maintenance therapy. b, c Kaplan–Meier curves describing cumulative event rates for the composite of either a major adverse cardiovascular or cerebrovascular event (MACCE) or bleeding event after stratifying by initial therapy: b clopidogrel, c prasugrel/ticagrelor. Data shown across IM/PMs prescribed clopidogrel (Clop-IM/PM), IM/PMs prescribed prasugrel/ticagrelor (Alt-IM/PM), UM/RM/NMs prescribed clopidogrel (Clop-U/R/NM), and UM/RM/NMs prescribed prasugrel/ticagrelor (Alt-U/R/NM). *Due to rare occurrence, UM/RM/NMs switched to prasugrel/ticagrelor and IMs switched  to clopidogrel were not included in the outcome analysis. The unadjusted log-rank P value is provided. IM intermediate metabolizer, NM normal metabolizer, PM poor metabolizer, RM rapid metabolizer, UM ultrarapid metabolizer.

Back to article page